This new article publication from Acta Pharmaceutica Sinica B, discusses how a photodynamic nanohybrid system reverses hypoxia and augments anti-primary and metastatic tumour efficacy of immunotherapy.

Photodynamic immunotherapy is a promising strategy for cancer treatment.

However, the dysfunctional tumour vasculature results in tumour hypoxia and the low efficiency of drug delivery, which in turn restricts the anticancer effect of photodynamic immunotherapy.

The authors of this article designed photosensitive lipid nanoparticles.

The synthesised PFBT@Rox Lip nanoparticles could produce type I/II reactive oxygen species (ROS) by electron or energy transfer through PFBT under light irradiation.

Moreover, this nanosystem could alleviate tumour hypoxia and promote vascular normalisation through Roxadustat.

Upon irradiation with white light, the ROS produced by PFBT@Rox Lip nanoparticles in situ dysregulated calcium homeostasis and triggered endoplasmic reticulum stress, which further promoted the release of damage-associated molecular patterns, enhanced antigen presentation, and stimulated an effective adaptive immune response, ultimately priming the tumour microenvironment (TME) together with the hypoxia alleviation and vessel normalisation by Roxadustat.

In vivo results indicated that PFBT@Rox Lip nanoparticles promoted M1 polarisation of tumour-associated macrophages, recruited more natural killer cells, and augmented infiltration of T cells, thereby leading to efficient photodynamic immunotherapy and potentiating the anti-primary and metastatic tumour efficacy of PD-1 antibody.

Collectively, photodynamic immunotherapy with PFBT@Rox Lip nanoparticles efficiently programme TME through the induction of immunogenicity and oxygenation, and effectively suppress tumour growth through immunogenic cell death and enhanced anti-tumour immunity.

Source: Compuscript Ltd